Nektar Therapeutics NKTR

NAS: NKTR | ISIN: US6402681083   14/05/2026
74,33 USD (-2,13%)
(-2,13%)   14/05/2026

7 mei 2026 · Nektar Therapeutics Reports First Quarter 2026 Financial Results · Persbericht

7 mei 2026 · Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics and Certain Officers - NKTR · Persbericht

5 mei 2026 · NKTR UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026 · Persbericht

1 mei 2026 · Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

1 mei 2026 · Nektar Therapeutics (NKTR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit · Persbericht

1 mei 2026 · Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics and Certain Officers - NKTR · Persbericht

30 april 2026 · NKTR INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026 · Persbericht

29 april 2026 · Nektar to Announce Financial Results for the First Quarter on Thursday, May 7, 2026, After Close of U.S.-Based Financial Markets · Persbericht

28 april 2026 · Bronstein, Gewirtz & Grossman LLC Urges Nektar Therapeutics Investors to Act: Class Action Filed Alleging Investor Harm · Persbericht

23 april 2026 · Nektar Therapeutics Announces Closing of $373.8 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares · Persbericht

22 april 2026 · Nektar Therapeutics Announces Pricing of Upsized $325 Million Public Offering · Persbericht

21 april 2026 · NKTR INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026 · Persbericht

20 april 2026 · Nektar Therapeutics Announces Proposed Public Offering · Persbericht

20 april 2026 · 52-Week Topline Results from 16-Week Blinded Treatment Extension of REZOLVE-AA Demonstrate Deepening of Responses in Severe-to-Very-Severe Alopecia Areata with Rezpegaldesleukin · Persbericht

19 april 2026 · Nektar to Hold Conference Call to Discuss 52-Week Topline Results from the 16-Week Extension Treatment Period for its REZOLVE-AA Phase 2b Study of Rezpegaldesleukin in Alopecia Areata on April 20, 2026 · Persbericht

16 april 2026 · Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics, Inc. and Certain Officers - NKTR · Persbericht

16 april 2026 · NKTR INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026 · Persbericht

16 april 2026 · NKTR Investor Alert: Nektar Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Hiding Enrollment Protocol Failures: SueWallSt · Persbericht

16 april 2026 · NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit · Persbericht

10 april 2026 · NKTR UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026 · Persbericht

Mijn selecties